Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Withdrawal in Plaque Psoriasis
NCT04239859Phase 4Not yet recruiting
- Sponsor
- Singapore General Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of secukinumab in plaque psoriasis, sponsored by Singapore General Hospital. Primary endpoint: Proportion of secukinumab treated participants free of relapse after withdrawal. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04239859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239859.